中光學(002189.SZ):公司整體訂單不足,開發的新整機上市還需要時間,目前還未形成批量
格隆匯1月12日丨中光學(002189.SZ)在投資者互動平台表示,公司研發項目均按計劃推進,成果轉化尚需一定時間。自2022年以來,消費電子市場持續低迷,銷庫存成為終端客户的首要任務,公司整體訂單不足,開發的新整機上市還需要時間,目前還未形成批量。公司將全力以赴拓市場促發展,加快"四新"產品開發,提高產品競爭力與附加值、提高公司的經濟效益,主動出清佔用資源較高、毛利率偏低的業務,並從多維度推進降本增效工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.